CI
ACOR

Cambiar Investors’s Acorda Therapeutics ACOR Stock Holding History

Cambiar Investors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,690
Closed -$7.63M – 180
2017
Q3 		$7.63M Sell
2,690
-4,488
-63% -$11.8M 0.12% 105
2017
Q2 		$17M Buy
7,178
+214
+3% +$424K 0.27% 67
2017
Q1 		$17.5M Buy
+6,964
New +$20M 0.29% 96

Other funds holding ACOR

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cambiar Investors's ACOR Position: Q4 2017 in Review

Cambiar Investors sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 2,690 shares — an estimated $7.63M sold.

Cambiar Investors first reported a position in ACOR in Q1 2017 and held it in 3 quarters. The position peaked at $17.5M in Q1 2017. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • Cambiar Investors reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Cambiar Investors sold 2,690 Acorda Therapeutics shares in Q4 2017, an estimated $7.63M.
  • Cambiar Investors first reported a position in Acorda Therapeutics in Q1 2017 and held it in 3 quarters.
  • Cambiar Investors's Acorda Therapeutics position peaked at $17.5M in Q1 2017.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on Cambiar Investors's 13F filing for Q4 2017, filed 30 Jan 2018.